THE ROLE OF THE UROKINASE SYSTEM IN LYMPHOGENOUS METASTASIS OF COLORECTAL CANCER

The aim of this work was to study the role and relationship of the levels of the components of the urokinase system with lymphogenous metastasis in patients with colorectal cancer.Materials and methods: the study was carried out on the basis of the Medical Scientific and Educational Center of the Moscow State University named after M.V. Lomonosov from 2019 to 2021. The study included healthy donors (control group) and patients with a verified diagnosis of stage I-III colorectal cancer in accordance with the inclusion criteria; all patients underwent surgical resection of the primary tumor with lymphadenectomy of the appropriate level. All patients underwent determination of the level of uPA and uPAR in blood serum before surgery. We also analyzed the clinical and demographic data of the patients, as well as the pathomorphological characteristics of the tumor.Results. The study included 7 healthy donors and 49 patients with stage I-III colorectal cancer. The average level of serum urokinase in the control group was 2.7±1.04 ng / ml, in the study group – 4, 15±1.9 ng / ml (p = 0.071), the level of the urokinase receptor in the control and study groups was 1.36 ±0.8 ng / ml vs 3.22±2.06 ng / ml (p = 0.05). The average level of serum urokinase in patients without and with lesions of lymph nodes was 3.4±1.4 ng / ml and 4.4±2.3 ng / ml (p = 0.068).Conclusion. There is a tendency to an increase in the level of components of the urokinase system in the peripheral blood in patients with colon neoplasms in the preoperative period, depending on the presence of metastatic lesions of regional lymph nodes, which indicates the need for further research in this area.

[1]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[2]  S. Rabbani,et al.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications , 2018, Front. Oncol..

[3]  H. Kuo,et al.  Stromal cell‐derived factor‐1/CXC receptor 4 and β1 integrin interaction regulates urokinase‐type plasminogen activator expression in human colorectal cancer cells , 2012, Journal of cellular physiology.

[4]  D. Berger,et al.  GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression. , 2010, Neoplasia.

[5]  H. Nielsen,et al.  Preoperative Plasma Soluble Urokinase Plasminogen Activator Receptor as a Prognostic Marker in Rectal Cancer Patients. An Eortc-Receptor and Biomarker Group Collaboration , 2005, The International journal of biological markers.

[6]  A. Mondino,et al.  uPA and uPAR in fibrinolysis, immunity and pathology. , 2004, Trends in immunology.

[7]  J. Curtis,et al.  Cutting Edge: Antigen-Driven Lymphocyte Recruitment to the Lung Is Diminished in the Absence of Urokinase-Type Plasminogen Activator (uPA) Receptor, but Is Independent of uPA1 , 2001, The Journal of Immunology.

[8]  F. Blasi,et al.  Proteolytic cleavage of the urokinase receptor substitutes for the agonist‐induced chemotactic effect. , 1996, The EMBO journal.

[9]  A. Vaheri,et al.  Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[11]  İ. Eray,et al.  Trends in colorectal cancer by subsite, age, and gender over a 15-year period in Adana, Turkey: 1993-2008. , 2013, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.